Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study

Irene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, Atul Deodhar, Thomas Rath, Bengt Hoepken, Oscar Irvin-Sellers, Karen Thomas, Lars Bauer, Martin Rudwaleit, Irene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, Atul Deodhar, Thomas Rath, Bengt Hoepken, Oscar Irvin-Sellers, Karen Thomas, Lars Bauer, Martin Rudwaleit

Abstract

Introduction: Acute anterior uveitis (AAU), affecting up to 40% of patients with axial spondyloarthritis (axSpA), risks permanent visual deficits if not adequately treated. We report 2-year results from C-VIEW, the first study to prospectively investigate certolizumab pegol (CZP) on AAU in patients with active axSpA at high risk of recurrent AAU.

Patients and methods: C-VIEW (NCT03020992) was a 104-week (96 weeks plus 8-week safety follow-up), open-label, multicenter study. Eligible patients had active axSpA, human leukocyte antigen-B27 (HLA-B27) positivity and a history of recurrent AAU (⩾2 AAU flares in total; ⩾1 in the year prior to baseline). Patients received CZP 400 mg at weeks 0, 2 and 4, then 200 mg every 2 weeks to week 96. The primary efficacy endpoint was the AAU flare event rate during 96 weeks' CZP versus 2 years pre-baseline.

Results: Of 115 enrolled patients, 89 initiated CZP (male: 63%; radiographic/non-radiographic axSpA: 85%/15%; mean disease duration: 9.1 years); 83 completed week 96. There was a significant 82% reduction in AAU flare event rate during CZP versus pre-baseline [rate ratio (95% confidence interval): 0.18 (0.12-0.28), p < 0.001]. One hundred percent and 59.6% of patients experienced ⩾1 and ⩾2 AAU flares pre-baseline, respectively, compared to 20.2% and 11.2% during treatment. Age, sex and axSpA population subgroup analyses were consistent with the primary analysis. There were substantial improvements in axSpA disease activity with no new safety signal identified.

Conclusion: CZP treatment significantly reduced AAU flare event rate in patients with axSpA and a history of AAU, indicating CZP is a suitable treatment option for patients at risk of recurrent AAU.

Trial registration clinicaltrialsgov: NCT03020992, URL: https://ichgcp.net/clinical-trials-registry/NCT03020992.

Keywords: TNF inhibitor; axial spondyloarthritis; extra-articular manifestations; uveitis.

Conflict of interest statement

Conflict of interest statement: Irene E. van der Horst-Bruinsma: Honoraria/consulting fees/research grants from AbbVie, BMS, MSD, Novartis, Pfizer, UCB Pharma; Rianne E. van Bentum: none; Frank D. Verbraak: Honoraria/consulting fees/research grants from Bayer, Novartis, IDxDR, UCB Pharma; Atul Deodhar: Honoraria/consulting fees/research grants from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB Pharma; Thomas Rath: Honoraria/consulting fees from AbbVie, BMS, Chugai, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB Pharma; Bengt Hoepken, Oscar Irvin-Sellers, Lars Bauer: Employees of UCB Pharma; Karen Thomas: Former contractor with UCB Pharma; Martin Rudwaleit: Honoraria/consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, UCB Pharma.

© The Author(s), 2021.

Figures

Figure 1.
Figure 1.
A. Percentage of patients experiencing 0, 1 or ⩾2 AAU flares. B. Mean number of AAU flares per patient. C. Poisson-adjusted AAU event rate per 96 weeks. Full analysis set (N = 89). AAU, acute anterior uveitis; CZP, certolizumab pegol; Q2W, every 2 weeks.
Figure 2.
Figure 2.
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89). Observed data are shown. ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity index; SD, standard deviation.
Figure 3.
Figure 3.
ASAS20, ASAS40 and ASAS partial remission response rates. Safety set (N = 89). Observed data are shown. ASAS, Assessment of SpondyloArthritis international Society; PR, partial remission.

References

    1. Biggioggero M, Crotti C, Becciolini A, et al.. The management of acute anterior uveitis complicating spondyloarthritis: present and future. Biomed Res Int 2018; 2018: 9460187.
    1. Bacchiega ABS, Balbi GGM, Ochtrop MLG, et al.. Ocular involvement in patients with spondyloarthritis. Rheumatology (Oxford) 2017; 56: 2060–2067.
    1. Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002; 20: S143–S145.
    1. Frantz C, Portier A, Etcheto A, et al.. Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients. Clin Exp Rheumatol 2019; 37: 26–31.
    1. De Winter JJ, Van Mens LJ, Van Der Heijde D, et al.. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther 2016; 18: 196.
    1. Rudwaleit M, Haibel H, Baraliakos X, et al.. The early disease stage in axial spondylarthritis: results from the German spondyloarthritis inception cohort. Arthritis Rheum 2009; 60: 717–727.
    1. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008; 67: 955–959.
    1. O’Rourke M, Haroon M, Alfarasy S, et al.. The effect of anterior uveitis and previously undiagnosed spondyloarthritis: results from the DUET cohort. Rheumatology 2017; 44: 1347–1354.
    1. Gutteridge IF, Hall AJ. Acute anterior uveitis in primary care. Clin Exp Optom 2007; 90: 70–82.
    1. Lim CSE, Sengupta R, Gaffney K. The clinical utility of human leucocyte antigen B27 in axial spondyloarthritis. Rheumatology 2017; 57: 959–968.
    1. Zheng MQ, Wang YQ, Lu XY, et al.. Clinical analysis of 240 patients with HLA-B27 associated acute anterior uveitis. Eye Sci 2012; 27: 169–172.
    1. Rademacher J, Poddubnyy D, Pleyer U. Uveitis in spondyloarthritis. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20951733.
    1. Calvo-Río V, Blanco R, Santos-Gómez M, et al.. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum 2016; 46: 95–101.
    1. Lie E, Lindström U, Zverkova-Sandström T, et al.. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 2017; 76: 1515–1521.
    1. Braun J, Baraliakos X, Listing J, et al.. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447–2451.
    1. Guignard S, Gossec L, Salliot C, et al.. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006; 65: 1631–1634.
    1. Rudwaleit M, Rødevand E, Holck P, et al.. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009; 68: 696–701.
    1. Van Bentum RE, Heslinga SC, Nurmohamed MT, et al.. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab – the GO-EASY study. Rheumatology 2019; 46: 153–159.
    1. Van Denderen JC, Visman IM, Nurmohamed MT, et al.. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. Rheumatology 2014; 41: 1843–1848.
    1. Ward MM, Deodhar A, Gensler LS, et al.. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res 2019; 71: 1285–1299.
    1. Van Der Heijde D, Ramiro S, Landewé R, et al.. 2016 Update of the ASAS–EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76: 978–991.
    1. Food and Drug Adninistration. HUMIRA (adalimumab). Product information: Abbott Laboratories, North Chicago, IL, USA. (2008; accessed 28 October 2020).
    1. Food and Drug Adninistration. CIMZIA (certolizumab pegol). Product information: UCB, Inc., Smyrna, GA, USA. (2019; accessed 30 October 2020).
    1. Landewé R, Braun J, Deodhar A, et al.. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 2014; 73: 39–47.
    1. Deodhar A, Gensler LS, Kay J, et al.. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2019; 71: 1101–1111.
    1. Rudwaleit M, Rosenbaum JT, Landewé R, et al.. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res 2016; 68: 838–844.
    1. Van Der Heijde D, Dougados M, Landewé R, et al.. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford) 2017; 56: 1498–1509.
    1. Van Der Horst-Bruinsma I, Van Bentum R, Verbraak FD, et al.. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open 2020; 6: e001161.
    1. Rudwaleit M, Van Der Heijde D, Landewé R, et al.. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777–783.
    1. Agresti A. Generalized linear models. In: Agrest A. (ed) An introduction to categorical data analysis. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007.
    1. Wright GC, Kaine J, Deodhar A. Understanding differences between men and women with axial spondyloarthritis. Semin Arthritis Rheum 2020; 50: 687–694.
    1. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al.. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795–810.
    1. Bessette AP, Sharma S. Adalimumab for noninfectious uveitis. Ophthalmol Retina 2017; 1: 179–180.
    1. Reveille JD, Hirsch R, Dillon CF, et al.. The prevalence of HLA–B27 in the US: data from the US national health and nutrition examination survey, 2009. Arthritis Rheum 2012; 64: 1407–1411.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj